Description | SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively. | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Related Catalog |
Signaling Pathways
>>
Autophagy
>>
Autophagy
Research Areas
>>
Cancer
|
||||||||||||
Target |
IC50: 790 nM (Rev-ErbBα), 560 nM (Rev-ErbBβ)[1] |
||||||||||||
In Vitro | SR9011 dose-dependently increases the REV-ERB-dependent repressor activity assessed in HEK293 cells expressing a chimeric Gal4 DNA Binding Domain (DBD) - REV-ERB ligand binding domain (LBD) α or β and a Gal4-responsive luciferase reporter (REV-ERBα IC50=790 nM, REV-ERBβ IC50=560 nM). SR9011 potently and efficaciously suppresses transcription in a cotransfection assay using full-length REV-ERBα along with a luciferase reporter driven by the Bmal1 promoter (SR9011 IC50=620 nM). SR9011 suppresses the expression ofBMAL1 mRNA in HepG2 cells in a REV-ERBα/β-dependent manner[1] SR9011 suppresses proliferation of the breast cancer cell lines regardless of their ER or HER2 status. SR9011 appears to pause the cell cycle of the breast cancer cells prior to M phase. Cyclin A (CCNA2) is identified as a direct target gene of REV-ERB suggesting that suppression of expression of this cyclin by SR9011 may mediate the cell cycle arrest. Treatment with SR9011 results in an increase in cells in the G0/G1 phase and a decrease of cells in S and G2/M phase suggesting that activation of REV-ERB may be resulting in decreased transition from G1 to S phase and/or from S to G2/M phase[2]. | ||||||||||||
In Vivo | SR9011 displays reasonable plasma exposure, thus, the expression of REV-ERB responsive genes is examined in the liver of mice treated with various doses of SR9011 for 6-days. The plasminogen activator inhibitor type 1 gene (Serpine1) is a REV-ERB target gene and displays dose-dependent suppression of expression in response to SR9011. The cholesterol 7α-hydroxylase (Cyp7a1) and sterol response element binding protein (Srepf1) genes have also been shown to be responsive to REV-ERB and are dose-dependently suppressed with increasing amounts of SR9011. After 12 days in D:D conditions mice are injected with a single dose of SR9011 or vehicle at CT6 (peak expression of Rev-erbα). Vehicle injection causes no disruption in circadian locomotor activity. However, administration of a single dose of SR9011 results in loss of locomotor activity during the subject dark phase. Normal activity returns the next circadian cycle, consistent with clearance of the drugs in less than 24h. The SR9011-dependent decrease in wheel running behavior in the mice under constant darkness conditions is dose-dependent and that the potency (ED50=56 mg/kg) is similar to the potency of SR9011-mediated suppression of a REV-ERB responsive gene, Srebf1 , in vivo (ED50=67mg/kg)[1]. | ||||||||||||
Solvent |
In Vitro:
DMSO : ≥ 43 mg/mL (89.76 mM) * "≥" means soluble, but saturation unknown. |
||||||||||||
Solubility |
|
||||||||||||
Cell Assay | MCF10A, MDA-MB-231, MCF-7, MDA-MB-361, SKBR3, BT474 cells are plated in 6-well plates one day before treatment. The MTT cell proliferation assays are performed. Briefly, 3×103 to 5 × 103 cells per well are plated in 96-well plates. Twenty-four hours later, cells are treated with SR9011 (0, 2, 4, 6, 8 and 10 μM) or DMSO. Seventy-two hours after treatment, the cells are labeled with 1.2 mM MTT and incubated for 4 hours. DMSO is then added and readings are taken on a plate reader at 540 nm[2]. | ||||||||||||
Animal Admin | Mice[1] For circadian gene expression experiments male C57BL6 mice (8-10 weeks of age) are either maintained on a L:D (12h:12h) cycle or on constant darkness. At circadian time (CT) 0 animals are administered a single dose of 100 mg/kg SR9011 (i.p.) and groups of animals (n=6) are sacrificed at CT0, CT6, CT12 and CT18. Gene expression is determined by real time QPCR. | ||||||||||||
Storage |
|
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere | ||||||||||||
SMILES | O=C(N1CC(CN(CC2=CC=C(Cl)C=C2)CC3=CC=C([N+]([O-])=O)S3)CC1)NCCCCC |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 642.8±50.0 °C at 760 mmHg |
Molecular Formula | C 23 H 31 ClN 4 O 3 S |
Molecular Weight | 479.035 |
Flash Point | 342.6±30.1 °C |
Exact Mass | 478.180542 |
LogP | 5.74 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.595 |
Name | CAS | Appearance |
Ethyl 2-phenylacetoacetate | 5413-05-8 | White powder |
Diethyl(phenylacetyl)malonate | 20320-59-6 | White powder |
BMK methyl glycidate | 80532-66-7 | Yellow liquid |
3-OXO-4-PHENYL-BUTYRIC ACID ETHYL ESTER | 718-08-1 | Clear liquid |
1-(benzo[d][1,3]dioxol-5-yl)-2-bromopropan-1-one | 52190-28-0 | Brown powder |
PMK ethyl glycidate | 28578-16-7 | Brown liquid |
2-Benzylamino-2-methyl-1-propanol | 10250-27-8 | White powder |
2-iodo-1-p-tolyl-propan-1-one | 236117-38-7 | Yellow powder |
1-(Benzyloxycarbonyl)-4-piperidinone | 19099-93-5 | White powder |
1-BOC-4-(4-FLUORO-PHENYLAMINO)-PIPERIDINE | 288573-56-8 | White powder |
1-BOC-4-(4-BROMO-PHENYLAMINO)-PIPERIDINE | 443998-65-0 | White powder |
1-Phenyl-2-nitropropene | 705-60-2 | Yellow diamond crystal |
docosyltrimethylammonium methyl sulphate | 81646-13-1 | White flake |
2-Amino-4-phenylbutane | 22374-89-6 | Transparent crystal |
Tetramisole hydrochloride | White powder Contained crystal | |
N-Isopropylbenzylamine | 102-97-6 | Clear crystal pink blue |
Valerophenone | 1009-14-9 | Clear liquid or Yellow liquid |
4'-Methylpropiophenone | 5337-93-9 | Clear liquid or Yellow liquid |
Tryptamine | 61-54-1 | White powder |
Dimethyl terephthalate | 120-61-6 | Colorless rhombic crystal system crystal |
Valerophenone | 1009-14-9 | White liquid |
N-(2,6-Dimethylphenl)-2-Piperidine Carboxamide | 15883-20-2 | White powder |
4-Methylpropiophenone | 5337-93-9 | Yellow liquid |
Benzylisopropylamine | 102-97-6 | Transparent crystal, transparent column, pink, blue |
5-Nitro-2-(bromoacetamido)benzophenone | 2011-70-3 | |
Nitazoxanide | 55981-09-4 | White powder |
1H-Indole-5,6-diol | 3131-52-0 | White powder |
D-Tartaric acid | 147-71-7 | White powder |
L-(+)-Tartaric acid | 526-83-0 | White powder |
L(+)-Tartaric acid | 87-69-4 | White powder |
DL-Tartaric acid | 133-37-9 | White powder |
1-Boc-3-Piperidinone | 98977-36-7 | Yellow powder |
tert-butyl 4-(4-bromoanilino)piperidine-1-carboxylate | 443998-65-0 | White powder |
tert-butyl 4-(4-fluoroanilino)piperidine-1-carboxylate | 288573-56-8 | White powder |
N-Benzyl-4-piperidone | 3612-20-2 | Yellow liquid |
4-oxopiperidinium chloride | 41979-39-9 | Yellow powder |
N-Phenyl-4-biphenylamine | 32228-99-2 | White powder |
N-BOC-aniline | 3422/1/3 | White powder |
4'-Methoxypropiophenone | 121-97-1 | White powder |
2-iodo-1-p-tolylpropan-1-one | 236117-38-7 | Yellow powder |
2-bromo-1-phenylhexan-1-one | 59774-06-0 | Yellow liquid |
2-iodo-1-phenyl-pentane-1-one | 124878-55-3 | Yellow liquid |
hexanophenone | 942-92-7 | White liquid |
2-(2-chlorophenyl)cyclohexan-1-one | 91393-49-6 | Yellow liquid |
2-Oxiranecarboxylicacid, 3-(1,3-benzodioxol-5-yl)-2-methyl-, ethyl ester | 28578-16-7 | Yellow liquid,Yellow powder,White powder |
1-Bromocyclopentyl-o-chlorophenyl ketone | White powder | |
Nicotinamide riboside chloride | 23111-00-4 | White powder |
1,4-Dimethoxy-2-(2-nitroethenyl) benzene | 40276-11-7 | Brown red color,White powder |
1-Phenyl-2-nitropropene | 705-60-2 | Yellow powder |
Loperamide hydrochloride | 34552-83-5 | White powder |
N-Benzyl-4-piperidone | 3612-20-2 | Yellow liquid |
1-Boc-3-Piperidinone | 98977-36-7 | Yellow powder |
Diethyl(phenylacetyl)malonate | 20320-59-6 | Brown red liquid |
(2S)-2-Ethylbutyl 2-(((perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate | 1911578-98-7 | White powder |
Tetramisole hydrochloride | White powder | |
Piperidin-4-one hydrochloride | 41979-39-9 | White powder |
5-(2-Fluorophenyl)-1H-pyrrole-3-carbonitrile | 1240948-77-9 | White powder |
5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde | 881674-56-2 | White powder |
5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde | 881677-11-8 | White powder |
Pyridine-3-sulfonyl chloride | 16133-25-8 | White powder |
1-Boc-3-piperidone | 98977-36-7 | Yellow powder |
(R)-7-(Benzyloxy)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione | 1985607-70-2 | White powder |
Loperamide hydrochloride | 34552-83-5 | White powder |
3-Benzyloxy-4-oxo-4H-pyran-2-carboxylic acid | 119736-16-2 | White powder |
methyl-2-methyl-3-phenylglycidate | 80532-66-7 | White powder |
N-Carbethoxy-4-piperidone | 29976-53-2 | Yellow liquid |
N-[(S)-(4-nitrophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester | 1354823-36-1 | White powder |
Benzyl alcohol | 100-51-6 | White liquid,White powder |
2-Bromo-4-fluoroaniline | 1003-98-1 | Yellow liquid |
Albendazole | 54965-21-8 | White powder |
Cysteamine Hydrochloride | 156-57-0 | White powder |
Olmesartan medoxomil | 144689-63-4 | White powder |
Florfenicol | 76639-94-6 | White powder |
Sulfanilamide | 63-74-1 | White grain |
Nafamostat mesylate | 82956-11-4 | White powder |
Dexmedetomidine | 113775-47-6 | White powder |
Bromadol | 77239-98-6 | White powder |
Cedrol | 77-53-2 | White powder |
Ferrous sulfate heptahydrate | 7782-63-0 | Light green powder |
1-Bromo-3,5-dimethyladamantane | 941-37-7 | Clear liquid |
1,3-Dimethyladamantane | 702-79-4 | Clear liquid |
docosyl-trimethyl-azanium; sulfonatooxymethane | 81646-13-1 | White flake |
Anethole | 4180-23-8 | Clear liquid |
3-Amino-1-hydroxyadamantane | 702-82-9 | White powder |
Furosemide | 54-31-9 | White powder |
2-Piperidone | 675-20-7 | White powder |
Levobupivacaine hydrochloride | 27262-48-2 | White powder |
8-ETHYL-5,8-DIHYDRO-5-OXO-2-[1-PIPERAZINYL]PYRIDO[2,3-D]-PYRIMIDINE-6-CARBOXYLIC ACID | 51940-44-4 | White powder |
Dihydroxyacetone (1,3-Dihydroxyacetone) | 96-26-4 | White powder |
Denatonium | 3734-33-6 | White powder |
Benzoate | 532-32-1 | White powder |
2-ethylhexanol | 104-76-7 | White powder,Clear liquid |
triacetin | 102-76-1 | Clear liquid |
Cesium chloride (Caesium chloride) | 7647-17-8 | White powder |